Soluble thrombomodulin attenuates sinusoidal obstruction syndrome in rat through suppression of high mobility group box 1

Liver International

Volumn 34, Issue 10, 2014, Pages 1473-1487

  Nakamura, Kojiro ^a   Hatano, Etsuro ^a   Miyagawa Hayashino, Aya ^b   Okuno, Masayuki ^a   Koyama, Yukinori ^a   Narita, Masato ^c   Seo, Satoru ^a   Taura, Kojiro ^a   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

High mobility group box 1; Intracellular adhesion molecule 1; Neutrophil; Receptor for advanced glycation end products; Recombinant human soluble thrombomodulin; Sinusoidal obstruction syndrome

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; MONOCROTALINE; MYELOPEROXIDASE; RECOMBINANT THROMBOMODULIN; ANTINEOPLASTIC AGENT; HBP1 PROTEIN, RAT; RECOMBINANT PROTEIN; THROMBOMODULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL VEIN; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER HEMORRHAGE; LIVER HISTOLOGY; LIVER NECROSIS; LIVER VENOOCCLUSIVE DISEASE; MACROPHAGE; MALE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PARTIAL HEPATECTOMY; PROTEIN BLOOD LEVEL; RAT; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL; SURVIVAL RATE; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; ELECTRON MICROSCOPY; HEPATIC VENO-OCCLUSIVE DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LIVER RESECTION; METABOLISM; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATECTOMY; HEPATIC VENO-OCCLUSIVE DISEASE; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIER ESTIMATE; MALE; MICROSCOPY, ELECTRON; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; THROMBOMODULIN;

EID: 84908084367     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12420     Document Type: Article

References (45)

1. Lochan R, White SA, Manas DM. Liver resection for colorectal liver metastasis. Surg Oncol 2007; 16: 33-45.
2. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 2003; 17: 63-70.
3. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-6.
4. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247: 118-24.
5. Tamandl D, Klinger M, Eipeldauer S, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 2011; 18: 421-30.
6. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 718-21.
7. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41.
8. Kashiwadate T, Miyagi S, Hara Y, et al. Recombinant human soluble thrombomodulin (ART-123) prevents warm ischemia-reperfusion injury in liver grafts from non-heart-beating donors. Transplant Proc 2012; 44: 369-72.
9. Uchiba M, Okajima K, Murakami K, et al. Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol 1996; 271: L470-5.
10. Ozaki T, Anas C, Maruyama S, et al. Intrarenal administration of recombinant human soluble thrombomodulin ameliorates ischaemic acute renal failure. Nephrol Dial Transplant 2008; 23: 110-9.
11. Ikezoe T, Yang J, Nishioka C, et al. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. Arterioscler Thromb Vasc Biol 2012; 32: 2259-70.
12. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008; 14: 476-84.
13. Mullins GE, Sunden-Cullberg J, Johansson AS, et al. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand J Immunol 2004; 60: 566-73.
14. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115: 1267-74.
15. Narita M, Hatano E, Ikai I, et al. A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction. Ann Surg 2009; 249: 806-13.
16. Nakamura K, Hatano E, Narita M, et al. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9. J Hepatol 2012; 57: 1037-43.
17. DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999; 29: 1779-91.
18. Yamanaka K, Hatano E, Narita M, et al. Olprinone attenuates excessive shear stress through up-regulation of endothelial nitric oxide synthase in a rat excessive hepatectomy model. Liver Transpl 2011; 17: 60-9.
19. Watanabe T, Keino H, Sato Y, et al. High mobility group box protein-1 in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2009; 50: 2283-90.
20. Dorman RB, Gujral JS, Bajt ML, Farhood A, Jaeschke H. Generation and functional significance of CXC chemokines for neutrophil-induced liver injury during endotoxemia. Am J Physiol Gastrointest Liver Physiol 2005; 288: G880-6.
21. Adams DH, Wang L, Hubscher SG, Neuberger JM. Hepatic endothelial cells. Targets in liver allograft rejection? Transplantation 1989; 47: 479-82.
22. Liu A, Dirsch O, Fang H, et al. HMGB1 in ischemic and non-ischemic liver after selective warm ischemia/reperfusion in rat. Histochem Cell Biol 2011; 135: 443-52.
23. Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol 2000; 7: 53-8.
24. Feng L, Zhu M, Zhang M, et al. Amelioration of compound 4, 4′-diphenylmethane-bis(methyl)carbamate on high mobility group box1-mediated inflammation and oxidant stress responses in human umbilical vein endothelial cells via RAGE/ERK1/2/NF-κB pathway. Int Immunopharmacol 2012; 15: 206-16.
25. Benimetskaya L, Wu S, Voskresenskiy AM, et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 2008; 112: 4343-52.
26. Peres E, Kintzel P, Dansey R, et al. Early intervention with antithrombin III therapy to prevent progression of hepatic venoocclusive disease. Blood Coagul Fibrinolysis 2008; 19: 203-7.
27. Inukai T, Sugita K, Goi K, et al. Prevention of hepatic veno-occlusive disease by a combination of heparin and prostaglandin E1 in children undergoing hematopoietic stem cell transplantation. Rinsho Ketsueki 2004; 45: 297-303.
28. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834-40.
29. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32-8.
30. DeLeve LD, Ito Y, Bethea NW, et al. Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastrointest Liver Physiol 2003; 284: G1045-52.
31. Deleve LD, Wang X, Tsai J, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 2003; 125: 882-90.
32. Ikezoe T, Togitani K, Komatsu N, Isaka M, Yokoyama A. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 783-5.
33. Ohwada C, Takeuchi M, Kawaguchi T, et al. Successful treatment with recombinant soluble thrombomodulin of two cases of sinusoidal obstructive syndrome/hepatic veno-occlusive disease after bone marrow transplantation. Am J Hematol 2011; 86: 886-8.
34. Nakamura D, Yoshimitsu M, Kawada H, et al. Recombinant human soluble thrombomodulin for the treatment of hepatic sinusoidal obstructive syndrome post allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47: 463-4.
35. Nakashima M, Kanamaru M, Umemura K, Tsuruta K. Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers. J Clin Pharmacol 1998; 38: 40-4.
36. Lai CH, Shi GY, Lee FT, et al. Recombinant Human Thrombomodulin Suppresses Experimental Abdominal Aortic Aneurysms Induced by Calcium Chloride in Mice. Ann Surg 2013; 258: 1103-10.
37. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11: 91-9.
38. Ding HS, Yang J, Gong FL, et al. High mobility group box 1 mediates neutrophil recruitment in myocardial ischemia-reperfusion injury through toll like receptor 4-related pathway. Gene 2012; 509: 143-53.
39. Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol 1996; 156: 2558-65.
40. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
41. Huang YH, Wang PW, Tiao MM, et al. Glucocorticoid modulates high-mobility group box 1 expression and Toll-like receptor activation in obstructive jaundice. J Surg Res 2011; 170: e47-55.
42. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201: 1135-43.
43. Kamo N, Ke B, Ghaffari AA, et al. The ASC/Caspase-1/IL-1β signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia-reperfusion injury. Hepatology 2013; 58: 351-62.
44. Wang X, Sun R, Wei H, Tian Z. High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: interaction of γδ T cells with macrophages. Hepatology 2013; 57: 373-84.
45. Kearon C, Comp P, Douketis J, et al. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005; 3: 962-8.